Sarepta Gene Therapy Suspension - Search News

Order byBest matchMost fresh

News

Roche pauses Sarepta gene therapy shipments outside U.S.

Following Sarepta’s Lead, Roche Suspends Elevidys Shipments to Some Ex-US Countries

Discovered and developed by Sarepta Therapeutics, Elevidys is a gene therapy that won accelerated approval in June 2023 and full approval in June 2024. Roche partnered with Sarepta in December 2019, paying $1.15 billion upfront in cash and stock for the right to launch and market Elevidys outside the U.S.

Continue reading

Devdiscourse · 3d

Sarepta Suspends Gene Therapy Shipments After Tragic Deaths

Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Fierce Pharma2d

Roche halts Elevidys distribution in some countries, following Sarepta's lead in US

Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...

10don MSN

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results